Cardiotrophin-1 as an independent factor of early development of atherosclerotic changes in comorbid patients

Abstract

The prevalence of comorbidities is increasing worldwide today, therefore, the comorbid patient is gaining much attention from clinicians. The most widespread comorbidities include the combination of arterial hypertension (AH), type 2 diabetes mellitus (T2DM), and obesity (OB), thus determining a high cardiovascular risk and calling for a search for the most recent diagnostic capabilities to detect early development of complications in such patients. Cardiotrophin-1 (CTF-1) is a highly informative marker for the early development of cardiovascular complications in patients with combined AH pathology with T2DM and OB. Therefore, the determination of its properties is actively discussed worldwide. Key properties of this biomarker include its contribution to the regulation of cardiac remodeling, promitotic and proliferative properties, ability to induce cardiomyocyte hypertrophy, etc. The findings of studies showing a close relationship between the concentration of CTF-1 and the severity of left ventricular myocardial hypertrophy in patients with AH and T2DM are of great importance.